Our mission

Revolutionizing target discovery to improve healthspan.

About us

Arrive is a biotechnology company applying in-vivo target screening with machine learning to age-related diseases.

Founded in Silicon Valley, California

2019

Offices in

San Francisco & Singapore

PARTNERS

Our partners include Roche, FDA, Singapore General Hospital, and others.

Roche Logo Singapore General Hospital Logo
Highlights

Arrive is working with the FDA to establish standards for A.I. algorithms in pathology. Read the HTT pilot study paper.

Arrive Head of Biology Andrew Brack speaks at National Academy of Medicine meeting on Healthy Longevity.

Arrive Head of Biology Andrew Brack will speak at American Aging Association.

Evan Szu speaks at the Singapore Academy of Sciences.

Our Approach

In Vivo Target Screening

Traditional target discovery in pharma starts with in-vitro assays. While this approach works for some applications, it does not capture the interactions of age-related diseases. This has limited the success rates of therapeutics for complex diseases.

Arrive has developed a unique system to make in vivo target screening feasible. By combining machine learning, bioinformatics, and a proprietary knowledge database we make in vivo target discovery possible.

Liver

The liver is a major driver of regulating the body’s metabolism, ensuring homeostatic energy balance and regulating immune and even brain activity.  Approximately 1 in 4 adults globally have fatty liver disease (NAFLD) with increasing prevalence with age.  While ageing reduces the liver’s regenerative capacity, this can be resolved through lifestyle choices.¹

Liver illustration

Muscle

Muscle strength decreases on average of 10% per decade after age 40. Loss of or reduced mobility with age contributes to nearly 3 million fall injuries among the elderly in the US alone, contributing to nearly $50B in healthcare costs.  Loss of muscle, or sarcopenia, can be delayed or reversed by exercise.²

Muscle illustration

Brain

11-20% of people over 65 experience subjective cognitive decline resulting in >$300B in healthcare costs per year in the US alone. However some people can improve their symptoms with lifestyle modification, which indicates potential for new preventative therapies.³

brain illustration
Develop

Clarity from Complexity

Complex biologic data necessitates powerful computational approaches to unlock information. Our Coherence platform collects and synthesizes data to produce advanced deep learning models which autonomously drive better decisions at large scale.

In Collaboration with
Roche Logo
Resonance
0.914
Expert
0.868
Average
0.803
Novice
0.759

Transforming data interpretation

Arrive technology unravels complexity. Our Coherence platform delves deeper into in vivo data, capturing key patterns and information beyond existing approaches.

WHO'S INVOLVED

Arrive is a group of passionate experts from diverse fields and backgrounds. Our leadership includes Anuj Gaggar (CEO), Andrew Brack (Head of Biology), and Evan Szu (COO).

Connect

Partnering

Arrive evaluates in-licensing opportunities from discovery through clinical stage assets. Please contact us with non-confidential partnership proposals or inquiries about opportunities.

Contact Partnering

Support our Science

Arrive’s mission is to develop therapies through the power of in vivo screening. We are supported by  individuals and organizations that share this aspiration and welcome you to join us.

Contact Science

Careers

We invite inquiries from exceptional drug development, biology and engineering talent. Please send resume and cover letter.

Contact Careers